Venetoclax and gilteritinib combination for FLT3-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience

In this study, we report our experience on treating R/R F LT-3mut AML patients not qualifying for enrollment in clinical trials with VenGilt as off-label use. Of note, due to administrative issues in our country, all but one patient received previous gilteritinib monotherapy showing poor response and later added-on venetoclax. This sequential schedule is the main novelty of our experience and differs from the study by Daver et al., in which no patients previously received gilteritinib and the two agents were started together. Therefore, the addition of venetoclax in patients poorly responding to gilteritinib configures a strategy which might improve the management of R/R patients in a real-world setting.